DaVita Inc. (DVA)
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
- Symbol
- DVA
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Medical Care Facilities
- Market cap
- $11.43B
- 52 week range
- 101 - 247.49
Valuation
- Share price
- $178.69 (close of 2026-10-02)
- P/E (TTM)
- 14.39x
- Price to book
- -23.71x
- Price to free cash flow
- 7.10x
- Enterprise value
- $24.17B
- Book value per share
- $-7.54
Price performance
| Period | Change |
|---|---|
| 1 day | +1.33% |
| 5 days | +0.12% |
| 1 month | -0.39% |
| 3 months | -23.93% |
| 6 months | +22.74% |
| Year to date | +57.28% |
| 1 year | +35.27% |
| 3 years | +87.90% |
| 5 years | +52.79% |
| 10 years | +170.46% |
| All time | +4290.42% |
Members of Congress who disclosed DVA trades
Julie Johnson · Alan Armstrong
Super investors holding DVA
Warren Buffett (Berkshire Hathaway) · Ken Griffin (Citadel) · Ray Dalio (Bridgewater Associates)
Profitability and growth
- Return on equity
- -199.83%
- Return on invested capital
- 14.80%
- Return on assets
- 4.27%
- Return on capital employed
- 14.25%
- Gross margin
- 27.25%
- Net margin
- 5.47%
- EBITDA margin
- 20.22%
- Revenue growth
- 6.46%
- Net income growth
- -20.24%
- Free cash flow growth
- -10.63%
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 14.09%
- Current ratio
- 1.47x
- Net debt to EBITDA
- 4.60x
Latest reported year
- Period end
- 2025-12-31
- Fiscal year
- 2025
- Revenue
- $13.64B
- Cost of revenue
- $9.93B
- Gross profit
- $3.72B
- EBITDA
- $2.76B
- Net income
- $746.80M
- Earnings per share
- $10.06
- Interest expense
- $579.93M
- Shares outstanding
- 74.23M
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $13.64B | $3.72B | $746.80M | $10.06 |
| 2024-12-31 | $12.82B | $3.63B | $936.34M | $11.02 |
| 2023-12-31 | $12.14B | $3.08B | $691.53M | $7.62 |
| 2022-12-31 | $11.61B | $2.69B | $560.40M | $6.03 |
| 2021-12-31 | $11.62B | $2.99B | $978.45M | $9.30 |
| 2020-12-31 | $11.55B | $2.94B | $773.64M | $6.46 |
| 2019-12-31 | $11.39B | $2.75B | $810.98M | $5.29 |
| 2018-12-31 | $11.40B | $2.66B | $159.39M | $0.93 |
| 2017-12-31 | $10.88B | $2.88B | $663.62M | $3.52 |
| 2016-12-31 | $10.71B | $3.10B | $879.87M | $4.36 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 27.25% | 5.47% | -199.83% | 14.80% |
| 2024-12-31 | 28.32% | 7.31% | 236.53% | 15.52% |
| 2023-12-31 | 25.34% | 5.70% | 55.59% | 11.54% |
| 2022-12-31 | 23.21% | 4.83% | 63.98% | 9.16% |
| 2021-12-31 | 25.76% | 8.42% | 104.52% | 42.09% |
| 2020-12-31 | 25.47% | 6.70% | 49.38% | 29.86% |
| 2019-12-31 | 24.12% | 7.12% | 34.97% | 29.95% |
| 2018-12-31 | 23.33% | 1.40% | 4.08% | 35.35% |
| 2017-12-31 | 26.45% | 6.10% | 13.58% | 34.02% |
| 2016-12-31 | 28.98% | 8.22% | 18.14% | 38.29% |
Cash and debt by year
| Period end | Cash |
|---|---|
| 2025-12-31 | $676.44M |
| 2024-12-31 | $794.93M |
| 2023-12-31 | $380.06M |
| 2022-12-31 | $244.09M |
| 2021-12-31 | $461.90M |
| 2020-12-31 | $324.96M |
| 2019-12-31 | $1.10B |
| 2018-12-31 | $323.04M |
| 2017-12-31 | $509.43M |
| 2016-12-31 | $675.98M |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $1.31B | $139.95M |
| 2024-12-31 | $1.47B | $102.79M |
| 2023-12-31 | $1.49B | $112.38M |
| 2022-12-31 | $961.14M | $95.43M |
| 2021-12-31 | $1.29B | $102.21M |
| 2020-12-31 | $1.30B | $91.46M |
| 2019-12-31 | $1.31B | $67.85M |
| 2018-12-31 | $784.50M | $73.06M |
| 2017-12-31 | $1.01B | $35.09M |
| 2016-12-31 | $1.14B | $38.34M |
Investor relations
Next earnings report
- Next confirmed report
- 2026-11-04
- Consensus EPS estimate
- $3.78
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-08-04 | Jun/2026 | $4.01 |
| 2026-05-05 | Mar/2026 | $2.41 |
| 2026-02-02 | Dec/2025 | $3.24 |
| 2025-10-29 | Sep/2025 | $3.29 |
| 2025-08-05 | Jun/2025 | $2.70 |
| 2025-05-12 | Mar/2025 | $1.75 |
| 2025-04-30 | - | - |
| 2025-02-13 | Dec/2024 | $2.21 |
Filings and sources
- Company website
- davita.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Universal Health Services Inc (UHS) · HCA Healthcare, Inc. (HCA) · Abbott Laboratories (ABT) · Molina Healthcare, Inc. (MOH) · Medtronic plc (MDT) · Centene Corp (CNC) · Stryker Corp (SYK) · Humana Inc (HUM)
Understanding these figures
Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades